Certara & Dizal Partner to Fast-Track FDA Approval of Sunvozertinib for Lung Cancer Case Study Certara & Dizal Partner to Fast-Track FDA Approval of Sunvozertinib for Lung Cancer Certara’s support enabled fast-track FDA oncology approval 2025 for Sunvozertinib, a breakthrough NSCLC therapy targeting…CertaraOctober 2, 2025
Best Practices in Clinical Pharmacology Gap Analysis Blog Best Practices in Clinical Pharmacology Gap Analysis September 19, 2025 Submitting your New Drug Application (NDA) to the FDA is the ultimate…CertaraSeptember 19, 2025
Certara Launches Libra™: AI-Powered Drug-Induced Liver Injury Prediction Tool Announcement Certara Launches Libra™: AI-Powered Drug-Induced Liver Injury Prediction Tool RADNOR, Pa. – September 17, 2025 – Certara, Inc. (Nasdaq: CERT), a global leader in…CertaraSeptember 17, 2025
Redefining Every Stage of Investment (RESI) Seed to Exit Conference Redefining Every Stage of Investment (RESI) Seed to Exit –CertaraSeptember 5, 2025
The Pharmacometrics Africa Conference 2025 (PMXAC-2025) Conference The Pharmacometrics Africa Conference 2025 (PMXAC-2025) CertaraSeptember 4, 2025
Certara Biotech Forum: Workshop on Developing Investor-Ready Strategies Live Events Certara Biotech Forum: Workshop on Developing Investor-Ready Strategies – London, UKCertaraSeptember 4, 2025
The Pursuit of Certainty: Integrated Evidence and the evolving drug development and reimbursement landscape On-Demand Webinar The Pursuit of Certainty: Integrated Evidence and the evolving drug development and reimbursement landscape Watch leading experts from Pfizer, Merck, Amicus, and Certara discuss how Integrated Evidence can bridge…CertaraSeptember 3, 2025
Designing a High-Value Drug Development Program: From Concept to First-in-Human (FIH) On-Demand Webinar Designing a High-Value Drug Development Program: From Concept to First-in-Human (FIH) Learn to design drug development programs for First-in-Human (FIH) success with biomarkers, PK/PD modeling, and…CertaraAugust 29, 2025
Model-Based Meta-Analysis (MBMA) at GSK: Real-World Impact on Strategy and Trials Blog Model-Based Meta-Analysis (MBMA) at GSK: Real-World Impact on Strategy and Trials GSK shares real-world case studies on how Model-Based Meta-Analysis (MBMA) supports dose selection, virtual control…CertaraJuly 31, 2025